|
|
||||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
REVIEW |
Correspondence to:
Abbreviations: CFS/ME, chronic fatigue syndrome/myalgic encephalomyelitis
I Gibson
Member of Parliament, Norwich North Constituency, House of Commons, London SW1A 0AA, UK
ABSTRACT
It has been 3 years since the Chief Medical Officer reported on chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and the time has come for a thorough investigation by an All Party Group drawn from the House of Commons and the House of Lords. We have received many written submissions and are engaged in taking oral evidence in 2-h sessions, which we open to the public as well as interested groups. The group has received a fantastic response to its requests for written evidence over the past few months. Questions that arise for a government response are the lack of provision and support for patients with CFS/ME, the issue of the clinical definition of CFS/ME, the need for a diagnostic test for CFS/ME, effectiveness of the National Institute for Clinical Excellence guidelines, and criteria used to decide which treatments are best for patients with CFS or myalgic encephalomyelitis.
HOME
HELP
FEEDBACK
SUBSCRIPTIONS
ARCHIVE
SEARCH
TABLE OF CONTENTS
REGISTER
Terms and conditions relating to subscriptions purchased online ¦ Website terms and conditions ¦ Privacy policy
Journal of Clinical Pathology
Molecular Pathology
Copyright © 2007 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.